Casdin Capital, LLC 13F holdings, Q4 2017
Casdin Capital, LLC disclosed 26 US equity positions worth $409.2m in its Q4 2017 13F filing. Its largest position is SG7 at 10.1% of the reported book, followed by FOUNDATION MEDICINE INC and LOXO ONCOLOGY INC. Versus Q3 2017 it opened 2 new positions, added to 13, reduced 1 and exited 2.
- $409m
- Reported equity book Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
- 26
- Positions Distinct securities in the equity book with a reported value above zero. Options are excluded.
- 10.1%
- Largest position The largest single position as a share of the reported equity book.
- 66.0%
- Top 10 weight The ten largest positions together, as a share of the reported equity book.
- 18
- Effective positions 1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
- 43
- Quarters on file since Q4 2015 Quarters for which this manager's 13F holdings are on record.
Holdings
Against Q3 2017: 2 new, 13 added, 1 reduced, 2 exited
| SG7 SAGE THERAPEUTICS INC | 10.1% | +4.2% | added |
| FOUNDATION MEDICINE INC no ticker | 8.7% | +8.3% | added |
| LOXO ONCOLOGY INC no ticker | 7.4% | 0.0% | held |
| 2655787D BLUEPRINT MEDICINES CORP | 6.4% | +17% | added |
| BLUEBIRD BIO INC no ticker | 6.3% | 0.0% | held |
| ALNY ALNYLAM PHARMACEUTICALS INC | 6.2% | 0.0% | held |
| MYOKEUR MYOKARDIA INC | 5.8% | 0.0% | held |
| SGMOQ SANGAMO THERAPEUTICS INC | 5.6% | 0.0% | held |
| GBTUSD GLOBAL BLOOD THERAPEUTICS IN | 5.0% | +36% | added |
| VYGR VOYAGER THERAPEUTICS INC | 4.6% | +39% | added |
| AGIO AGIOS PHARMACEUTICALS INC | 4.1% | +16% | added |
| FATE FATE THERAPEUTICS INC | 3.9% | +373% | added |
| ONCEEUR SPARK THERAPEUTICS INC | 3.8% | +44% | added |
| CDXS CODEXIS INC | 3.3% | +8.5% | added |
| EVH EVOLENT HEALTH INC | 3.2% | +36% | added |
| BOLDEUR AUDENTES THERAPEUTICS INC | 3.1% | 0.0% | held |
| GNMK GENMARK DIAGNOSTICS INC | 2.8% | +82% | added |
| ILMN ILLUMINA INC | 2.3% | 0.0% | held |
| CLVSEUR CLOVIS ONCOLOGY INC | 2.1% | 0.0% | held |
| JNCEEUR JOUNCE THERAPEUTICS INC | 1.5% | +19% | added |
| EDIT EDITAS MEDICINE INC | 1.0% | 0.0% | held |
| CTMX CYTOMX THERAPEUTICS INC. | 0.9% | 0.0% | held |
| SYRSEUR SYROS PHARMACEUTICALS INC | 0.7% | +7.0% | added |
| GILD GILEAD SCIENCES INC | 0.5% | – | new |
| ONC BEIGENE LTD | 0.4% | – | new |
| OVID OVID THERAPEUTICS INC | 0.4% | −23% | reduced |
Exited since Q3 2017
| KITE PHARMA INC no ticker | 5.4% | $19.1m |
| T8S TESARO INC | 1.4% | $5.0m |
Sector mix
Book over time
Every quarter on file (43)
| Quarter | Positions | Equity book |
|---|---|---|
| Q2 2026 | 43 | $2.0bn |
| Q1 2026 | 40 | $1.3bn |
| Q4 2025 | 38 | $1.6bn |
| Q3 2025 | 32 | $1.2bn |
| Q2 2025 | 33 | $1.1bn |
| Q1 2025 | 44 | $1.2bn |
| Q4 2024 | 38 | $1.5bn |
| Q3 2024 | 35 | $1.5bn |
| Q2 2024 | 38 | $1.3bn |
| Q1 2024 | 36 | $1.3bn |
| Q4 2023 | 36 | $1.0bn |
| Q3 2023 | 38 | $897m |
| Q2 2023 | 41 | $1.1bn |
| Q1 2023 | 40 | $1.2bn |
| Q4 2022 | 44 | $1.3bn |
| Q3 2022 | 36 | $1.5bn |
| Q2 2022 | 40 | $1.2bn |
| Q1 2022 | 47 | $2.2bn |
| Q4 2021 | 53 | $3.5bn |
| Q3 2021 | 53 | $4.0bn |
| Q2 2021 | 54 | $3.9bn |
| Q1 2021 | 48 | $3.4bn |
| Q4 2020 | 50 | $3.4bn |
| Q3 2020 | 45 | $2.2bn |
| Q2 2020 | 42 | $1.7bn |
| Q1 2020 | 38 | $942m |
| Q4 2019 | 31 | $1.1bn |
| Q3 2019 | 33 | $966m |
| Q2 2019 | 31 | $1.1bn |
| Q1 2019 | 29 | $910m |
| Q4 2018 | 31 | $585m |
| Q3 2018 | 34 | $814m |
| Q2 2018 | 32 | $709m |
| Q1 2018 | 30 | $565m |
| Q4 2017 | 26 | $409m |
| Q3 2017 | 26 | $354m |
| Q2 2017 | 31 | $250m |
| Q1 2017 | 29 | $170m |
| Q4 2016 | 25 | $121m |
| Q3 2016 | 26 | $123m |
| Q2 2016 | 24 | $95.7m |
| Q1 2016 | 25 | $84.5m |
| Q4 2015 | 27 | $107m |
Where Casdin Capital, LLC was early
| EDIT EDITAS MEDICINE INC | Q1 2016 | 2 of 96 | 3.5% | Held at last filing, Q2 2026 | −91% |
| ONC BEIGENE LTD | Q1 2016 | 9 of 104 | 1.1% | Exited by Q2 2025 | +829% |
| EVH EVOLENT HEALTH INC | Q2 2016 | 1 of 130 | 4.8% | Exited by Q2 2019 | −34% |
| T8S TESARO INC | Q2 2016 | 8 of 83 | 1.8% | Exited by Q4 2017 | +54% |
| MDRX ALLSCRIPTS HEALTHCARE SOLUTN | Q3 2016 | 8 of 96 | 2.1% | Exited by Q2 2017 | −3.7% |
| CDXS CODEXIS INC | Q1 2017 | 2 of 80 | 1.9% | Exited by Q3 2025 | −49% |
| PACB PACIFIC BIOSCIENCES CALIF IN | Q1 2017 | 3 of 118 | 2.1% | Held at last filing, Q2 2026 | −68% |
| SGMOQ SANGAMO THERAPEUTICS INC | Q1 2017 | 3 of 85 | 2.6% | Exited by Q3 2022 | −20% |
| FATE FATE THERAPEUTICS INC | Q2 2017 | 4 of 107 | 0.7% | Exited by Q1 2024 | +15% |
| CRSP CRISPR THERAPEUTICS AG | Q1 2018 | 1 of 120 | 1.1% | Exited by Q1 2022 | +66% |
| ZLAB ZAI LAB LTD | Q1 2018 | 6 of 99 | 0.5% | Exited by Q2 2022 | +106% |
| BLFS BIOLIFE SOLUTIONS INC | Q2 2018 | 1 of 78 | 1.6% | Held at last filing, Q2 2026 | +148% |
| CDNA CAREDX INC | Q2 2018 | 6 of 103 | 0.3% | Exited by Q2 2022 | +202% |
| CNST CONSTELLATION PHARMCETICLS I | Q3 2018 | 1 of 72 | 1.1% | Exited by Q3 2021 | – |
| 2JQ GRITSTONE ONCOLOGY INC | Q3 2018 | 2 of 62 | 1.3% | Exited by Q3 2020 | −53% |
| SRPT SAREPTA THERAPEUTICS INC | Q3 2018 | 14 of 182 | 0.8% | Held at last filing, Q2 2026 | −89% |
| DNLI DENALI THERAPEUTICS INC | Q4 2018 | 2 of 104 | 0.4% | Held at last filing, Q2 2026 | +24% |
| ALEC ALECTOR INC | Q1 2019 | 4 of 87 | 0.7% | Exited by Q1 2022 | +10% |
| TWST TWIST BIOSCIENCE CORP | Q2 2019 | 2 of 99 | 0.8% | Exited by Q3 2023 | −29% |
| ADPT ADAPTIVE BIOTECHNOLOGIES COR | Q2 2019 | 4 of 130 | 1.9% | Exited by Q2 2022 | −71% |
| FULC FULCRUM THERAPEUTICS INC | Q3 2019 | 1 of 95 | 0.6% | Exited by Q3 2021 | +58% |
| RVMD REVOLUTION MEDICINES INC | Q1 2020 | 1 of 164 | 3.1% | Held at last filing, Q2 2026 | +755% |
| DMTKQ DERMTECH INC | Q1 2020 | 2 of 47 | 0.6% | Exited by Q2 2022 | +31% |
| ALLO ALLOGENE THERAPEUTICS INC | Q1 2020 | 4 of 94 | 1.0% | Exited by Q1 2022 | −23% |
| GBIOGBX GENERATION BIO CO | Q2 2020 | 1 of 48 | 2.0% | Exited by Q2 2022 | −65% |
| RLAY RELAY THERAPEUTICS INC | Q3 2020 | 1 of 111 | 7.3% | Held at last filing, Q2 2026 | −56% |
| FDMT 4D MOLECULAR THERAPEUTICS IN | Q4 2020 | 1 of 94 | 1.0% | Exited by Q1 2025 | −87% |
| BEAM BEAM THERAPEUTICS INC | Q4 2020 | 3 of 98 | 1.1% | Held at last filing, Q2 2026 | −58% |
| ABCL ABCELLERA BIOLOGICS INC | Q4 2020 | 7 of 87 | 0.2% | Exited by Q2 2024 | −89% |
| IPSC CENTURY THERAPEUTICS INC | Q2 2021 | 3 of 51 | 2.4% | Held at last filing, Q2 2026 | −92% |
| TNYA TENAYA THERAPEUTICS INC | Q3 2021 | 1 of 53 | 1.8% | Held at last filing, Q2 2026 | −96% |
| ABSI ABSCI CORPORATION | Q3 2021 | 2 of 76 | 2.2% | Held at last filing, Q2 2026 | −0.3% |
| MXCT MAXCYTE INC | Q3 2021 | 2 of 63 | 4.3% | Exited by Q4 2023 | −74% |
| TNGX TANGO THERAPEUTICS INC | Q3 2021 | 2 of 103 | 1.8% | Exited by Q2 2025 | −89% |
| WGS GENEDX HOLDINGS CORP | Q3 2021 | 5 of 104 | 0.9% | Held at last filing, Q2 2026 | −73% |
| TSVT* 2SEVENTY BIO INC | Q1 2022 | 4 of 70 | 0.5% | Exited by Q2 2025 | −71% |
| PLRX PLIANT THERAPEUTICS INC | Q3 2022 | 8 of 103 | 1.0% | Exited by Q3 2024 | −49% |
| PRME PRIME MEDICINE INC | Q4 2022 | 3 of 62 | 1.1% | Held at last filing, Q2 2026 | −80% |
| GPCR STRUCTURE THERAPEUTICS INC | Q1 2023 | 1 of 114 | 1.3% | Held at last filing, Q2 2026 | +126% |
| NGNE NEUROGENE INC | Q4 2023 | 2 of 45 | 1.0% | Held at last filing, Q2 2026 | +62% |
| MAZE MAZE THERAPEUTICS INC | Q1 2025 | 9 of 82 | 0.9% | Held at last filing, Q2 2026 | +171% |
Concentration and tenure
- 12.9%
- Median largest position, all quarters The largest single position as a share of the reported equity book.
- 65.0%
- Median top 10 weight, all quarters The ten largest positions together, as a share of the reported equity book.
- Concentrated
- Style, by median largest position
- 3
- Median completed holding, quarters